| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniel J Drucke. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. vol 62. issue 10. 2013-12-10. PMID:23818527. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are incretin hormones that control the secretion of insulin, glucagon, and somatostatin to facilitate glucose disposal. |
2013-12-10 |
2023-08-12 |
human |
| M M van der Klauw, B H R Wolffenbutte. The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes. The Netherlands journal of medicine. vol 70. issue 10. 2013-12-03. PMID:23230012. |
the combination of insulin and glp-1 analogues in the treatment of type 2 diabetes. |
2013-12-03 |
2023-08-12 |
Not clear |
| M M van der Klauw, B H R Wolffenbutte. The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes. The Netherlands journal of medicine. vol 70. issue 10. 2013-12-03. PMID:23230012. |
theoretically, in type 2 diabetes mellitus patients, the combination of a glp-1 analogue with insulin seems attractive, because of the weight loss perceived in users of glp-1 analogues in contrast to the weight gain seen in most patients starting insulin therapy, leading to even more insulin resistance. |
2013-12-03 |
2023-08-12 |
Not clear |
| Rozita Shirazi, Vilborg Palsdottir, Jim Collander, Fredrik Anesten, Heike Vogel, Fanny Langlet, Alexander Jaschke, Annette Schürmann, Vincent Prévot, Ruijin Shao, John-Olov Jansson, Karolina Patrycja Skibick. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proceedings of the National Academy of Sciences of the United States of America. vol 110. issue 40. 2013-12-03. PMID:24048027. |
glucagon-like peptide 1 (glp-1), produced in the intestine and the brain, can stimulate insulin secretion from the pancreas and alleviate type 2 diabetes. |
2013-12-03 |
2023-08-12 |
mouse |
| Rozita Shirazi, Vilborg Palsdottir, Jim Collander, Fredrik Anesten, Heike Vogel, Fanny Langlet, Alexander Jaschke, Annette Schürmann, Vincent Prévot, Ruijin Shao, John-Olov Jansson, Karolina Patrycja Skibick. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proceedings of the National Academy of Sciences of the United States of America. vol 110. issue 40. 2013-12-03. PMID:24048027. |
the cytokine interleukin-6 (il-6) may enhance insulin secretion from β-cells by stimulating peripheral glp-1 production. |
2013-12-03 |
2023-08-12 |
mouse |
| Weijuan Shao, Zhaoxia Wang, Wilfred Ip, Yu-Ting Chiang, Xiaoquan Xiong, Tuanyao Chai, Catherine Xu, Qinghua Wang, Tianru Ji. GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro. American journal of physiology. Endocrinology and metabolism. vol 304. issue 12. 2013-11-26. PMID:23571712. |
furthermore, glp-1(28-36)amide treatment enhanced islet insulin secretion and increased the growth of ins-1 cells, which was associated with increased cyclin d1 expression. |
2013-11-26 |
2023-08-12 |
mouse |
| Ting C Zha. Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection. Cardiovascular diabetology. vol 12. 2013-11-26. PMID:23777457. |
a major advantage over conventional insulin is the fact that the insulinotropic actions of glp-1 are dependent upon ambient glucose concentration, mitigating the risks of hypoglycemia. |
2013-11-26 |
2023-08-12 |
human |
| David J Hodson, Ryan K Mitchell, Elisa A Bellomo, Gao Sun, Laurent Vinet, Paolo Meda, Daliang Li, Wen-Hong Li, Marco Bugliani, Piero Marchetti, Domenico Bosco, Lorenzo Piemonti, Paul Johnson, Stephen J Hughes, Guy A Rutte. Lipotoxicity disrupts incretin-regulated human β cell connectivity. The Journal of clinical investigation. vol 123. issue 10. 2013-11-26. PMID:24018562. |
we found that glp-1 and gip recruit a highly coordinated subnetwork of β cells that are targeted by lipotoxicity to suppress insulin secretion. |
2013-11-26 |
2023-08-12 |
mouse |
| Masato Takeuchi, Akira Hirasawa, Takafumi Hara, Ikuo Kimura, Tatsuya Hirano, Takayoshi Suzuki, Naoki Miyata, Takeo Awaji, Masaji Ishiguro, Gozoh Tsujimot. FFA1-selective agonistic activity based on docking simulation using FFA1 and GPR120 homology models. British journal of pharmacology. vol 168. issue 7. 2013-11-25. PMID:22639973. |
background and purpose the free fatty acid ffa1 receptor and gpr120 are gpcrs whose endogenous ligands are medium- and long-chain ffas, and they are important in regulating insulin and glp-1 secretion respectively. |
2013-11-25 |
2023-08-12 |
Not clear |
| Yoko Yamashita, Masaaki Okabe, Midori Natsume, Hitoshi Ashid. Cinnamtannin A2, a tetrameric procyanidin, increases GLP-1 and insulin secretion in mice. Bioscience, biotechnology, and biochemistry. vol 77. issue 4. 2013-11-25. PMID:23563558. |
cinnamtannin a2, a tetrameric procyanidin, increases glp-1 and insulin secretion in mice. |
2013-11-25 |
2023-08-12 |
mouse |
| Yoko Yamashita, Masaaki Okabe, Midori Natsume, Hitoshi Ashid. Cinnamtannin A2, a tetrameric procyanidin, increases GLP-1 and insulin secretion in mice. Bioscience, biotechnology, and biochemistry. vol 77. issue 4. 2013-11-25. PMID:23563558. |
cinnamtannin a2 specifically increased the glucagon-like peptide-1 (glp-1) and insulin secretion levels in the plasma after 60 min administration. |
2013-11-25 |
2023-08-12 |
mouse |
| Neale D Cohen, Ralph Audehm, Elaine Pretorius, Joey Kaye, Leon H Chapman, Stephen Colagiur. The rationale for combining GLP-1 receptor agonists with basal insulin. The Medical journal of Australia. vol 199. issue 4. 2013-11-19. PMID:23984780. |
the rationale for combining glp-1 receptor agonists with basal insulin. |
2013-11-19 |
2023-08-12 |
Not clear |
| Neale D Cohen, Ralph Audehm, Elaine Pretorius, Joey Kaye, Leon H Chapman, Stephen Colagiur. The rationale for combining GLP-1 receptor agonists with basal insulin. The Medical journal of Australia. vol 199. issue 4. 2013-11-19. PMID:23984780. |
• glucagon-like peptide-1 (glp-1) receptor agonists stimulate glucose-medicated insulin secretion, suppress glucagon secretion, delay gastric emptying and decrease appetite. |
2013-11-19 |
2023-08-12 |
Not clear |
| Neale D Cohen, Ralph Audehm, Elaine Pretorius, Joey Kaye, Leon H Chapman, Stephen Colagiur. The rationale for combining GLP-1 receptor agonists with basal insulin. The Medical journal of Australia. vol 199. issue 4. 2013-11-19. PMID:23984780. |
use of glp-1 receptor agonists in combination therapy with basal insulin offers an alternative approach to intensification of insulin therapy. |
2013-11-19 |
2023-08-12 |
Not clear |
| Neale D Cohen, Ralph Audehm, Elaine Pretorius, Joey Kaye, Leon H Chapman, Stephen Colagiur. The rationale for combining GLP-1 receptor agonists with basal insulin. The Medical journal of Australia. vol 199. issue 4. 2013-11-19. PMID:23984780. |
• prospective interventional trials demonstrate that glp-1 receptor agonists added to basal insulin decrease postprandial glucose levels, lower hba1c levels, decrease weight and lower basal insulin requirements without increasing the risk of major hypoglycaemic events. |
2013-11-19 |
2023-08-12 |
Not clear |
| Ping Deng, Alison N Beloshapka, Brittany M Vester Boler, Kelly S Swanso. Dietary fibre fermentability but not viscosity elicited the 'second-meal effect' in healthy adult dogs. The British journal of nutrition. vol 110. issue 5. 2013-11-18. PMID:23374235. |
the present study evaluated the effects of fibre fermentability and viscosity in a morning meal on glucose, insulin and glucagon-like peptide-1 (glp-1) responses to a glucose challenge later in the day in six healthy female dogs. |
2013-11-18 |
2023-08-12 |
Not clear |
| Ping Deng, Alison N Beloshapka, Brittany M Vester Boler, Kelly S Swanso. Dietary fibre fermentability but not viscosity elicited the 'second-meal effect' in healthy adult dogs. The British journal of nutrition. vol 110. issue 5. 2013-11-18. PMID:23374235. |
insulin and glp-1 iauc(0-180 min) were not affected. |
2013-11-18 |
2023-08-12 |
Not clear |
| Ping Deng, Alison N Beloshapka, Brittany M Vester Boler, Kelly S Swanso. Dietary fibre fermentability but not viscosity elicited the 'second-meal effect' in healthy adult dogs. The British journal of nutrition. vol 110. issue 5. 2013-11-18. PMID:23374235. |
in expt 2, baseline glp-1 was greater (p< 0.005) and baseline insulin was lower (p< 0.05) in dogs fed the hvf v. mvf diet, but glucose, insulin and glp-1 iauc(0-180) min were not affected. |
2013-11-18 |
2023-08-12 |
Not clear |
| M Rauchenzauner, M Laimer, M Wiedmann, A Tschoner, K Salzmann, W Sturm, A Sandhofer, G Walser, G Luef, C F Ebenbichle. The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? Epilepsy research. vol 104. issue 3. 2013-11-14. PMID:23182413. |
the novel insulin resistance parameters rbp4 and glp-1 in patients treated with valproic acid: just a sidestep? |
2013-11-14 |
2023-08-12 |
Not clear |
| M Rauchenzauner, M Laimer, M Wiedmann, A Tschoner, K Salzmann, W Sturm, A Sandhofer, G Walser, G Luef, C F Ebenbichle. The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? Epilepsy research. vol 104. issue 3. 2013-11-14. PMID:23182413. |
retinol-binding protein 4 (rbp4) and glucagon-like peptide-1 (glp-1) are considered as important new targets in modern type 2 diabetes mellitus therapy linked to insulin resistance, nafld and visceral obesity acting via peripheral or central mechanisms. |
2013-11-14 |
2023-08-12 |
Not clear |